Genzyme and vaccines push up Sanofi's first-quarter results

PARIS (Reuters) – Sanofi (PA:) upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar 31 percent sales increase at its rare diseases Genzyme unit.

The French drugmaker, which also posted a strong sales increase at its vaccines division confirmed its full-year outlook.

Net income rose 9 percent to 1.77 billion euros (£1.5 billion) at constant exchange rates in the first quarter on sales of 8.4 billion. Analysts polled by Reuters with Infront Data had forecast average net income of 1.67 billion euros and sales of 8.36 billion.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ SOURCE